FDMT News and Press, 4D Molecular Therapeutics Inc. From 04/15/24

2024-04-15 05:30:02 ET Barclays analyst issues OVERWEIGHT recommendation for FDMT on April 15, 2024 03:43AM ET. FDMT was trading at $26.35 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommend...

2024-04-01 09:15:05 ET Jefferies analyst issues BUY recommendation for FDMT on April 1, 2024 07:51AM ET. The previous analyst recommendation was Buy. FDMT was trading at $31.86 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2024-03-28 15:15:05 ET BMO Capital analyst issues OUTPERFORM recommendation for FDMT on March 28, 2024 01:31PM ET. The previous analyst recommendation was Outperform. FDMT was trading at $31.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-03-28 10:43:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts ...

Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate a...

Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 Positiv...

2024-02-20 05:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...

4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO 2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all five evaluable patients Cardiac biopsies were obtained fr...

2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...